by Year
NEWS 2011
Launch of an agent to treat Acute Promyelocytic Leukemia (APL) in Korea
KYOTO, JAPAN – (June 1, 2011) – Nippon Shinyaku Co., Ltd (Headquarters: Kyoto, Japan; President: Shigenobu Maekawa) today announced that BL&H Co., Ltd. (Headquarters: Seoul, Korea; President: Dong Chul Roh), a licensee of Nippon Shinyaku was notified of the reimbursement price of TRISENOX® Injection and has launched the product in Korea. TRISENOX® injection is indicated, in Korea, for induction of remission and consolidation in adult patients with relapsed/refractory APL.
TRISENOX® Injection is marketed in more than 10 countries in the USA and Europe. Nippon Shinyaku was licensed for TRISENOX® Injection from Cephalon, Inc. (Headquarters: Pennsylvania, USA.; CEO: Kevin Buchi) in December 2002 and launched the product in Japan in December 2004.
Nippon Shinyaku concluded the license agreement for TRISENOX® Injection with BL&H in November 2008, and the product was approved as an orphan drug in Korea in June 2010.
APL is a subtype of acute myeloid leukemia and the occurrence number of APL patients is presumed to be 500 to 700 in Japan, and around 250 in Korea annually.
TRISENOX® injection had high rates of complete remission for APL patients whose disease did not respond to initial treatment or relapsed. The safety and efficacy of TRISENOX® Injection was proved and the launch of the product will contribute to the treatment of relapsed or refractory APL patients also in Korea.
(Reference)
Company profile of BL&H
Corporate Name: BL&H Co., Ltd.
Established: October, 1999
President & CEO: Dong Chul Roh
Address: 9F, Dealim Office Valley, 97-3 Guro4-Dong, Guro-ku, Seoul,
Korea
Number of Employees: 40
Sales: 9,698 million KRW (in 2010)
Business line: Development and sales of pharmaceuticals